Bayer says Phase III Xarelto study halted early

BERLIN (Reuters) - Bayer and partner Johnson & Johnson suffered a setback for blockbuster clot prevention drug Xarelto, with the German company saying a Phase III study had been halted early after the drug showed no efficacy improvements over low-dose aspirin.